Technical Analysis for HRMY - Harmony Biosciences Holdings, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 29.40 | 1.27% | 0.37 |
HRMY closed up 1.27 percent on Friday, April 19, 2024, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Apr 30
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Oversold Stochastic | Weakness | 0.00% | |
| NR7 | Range Contraction | 1.27% | |
| NR7-2 | Range Contraction | 1.27% | |
| Doji - Bullish? | Reversal | 1.27% | |
| Oversold Stochastic | Weakness | 1.27% | |
| NR7 | Range Contraction | 0.72% | |
| Multiple of Ten Bearish | Other | 0.72% | |
| Oversold Stochastic | Weakness | 0.72% | |
| Stochastic Reached Oversold | Weakness | -1.28% | |
| Multiple of Ten Bearish | Other | -1.28% |
| Alert | Time |
|---|---|
| Possible NR7 | about 18 hours ago |
| Up 1% | about 19 hours ago |
| 60 Minute Opening Range Breakout | about 22 hours ago |
| Fell Below Previous Day's Low | about 22 hours ago |
| Possible NR7 | 2 days ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 04/30/2024
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc. was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. The company was founded in 2017 and is based in Plymouth Meeting, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Neurological Disorders Stage Pharmaceutical Ethers Urological Disorders Chloroarenes Narcolepsy Piperidines Rare Neurological Disorders Stimulants
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Neurological Disorders Stage Pharmaceutical Ethers Urological Disorders Chloroarenes Narcolepsy Piperidines Rare Neurological Disorders Stimulants
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 39.265 |
| 52 Week Low | 18.6112 |
| Average Volume | 396,672 |
| 200-Day Moving Average | 31.46 |
| 50-Day Moving Average | 31.85 |
| 20-Day Moving Average | 31.10 |
| 10-Day Moving Average | 29.78 |
| Average True Range | 1.38 |
| RSI (14) | 41.86 |
| ADX | 15.72 |
| +DI | 13.71 |
| -DI | 22.11 |
| Chandelier Exit (Long, 3 ATRs) | 30.29 |
| Chandelier Exit (Short, 3 ATRs) | 32.78 |
| Upper Bollinger Bands | 34.24 |
| Lower Bollinger Band | 27.97 |
| Percent B (%b) | 0.23 |
| BandWidth | 20.14 |
| MACD Line | -0.76 |
| MACD Signal Line | -0.55 |
| MACD Histogram | -0.2088 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 30.59 | ||||
| Resistance 3 (R3) | 30.50 | 30.02 | 30.39 | ||
| Resistance 2 (R2) | 30.02 | 29.72 | 30.06 | 30.32 | |
| Resistance 1 (R1) | 29.71 | 29.53 | 29.87 | 29.80 | 30.26 |
| Pivot Point | 29.23 | 29.23 | 29.31 | 29.27 | 29.23 |
| Support 1 (S1) | 28.92 | 28.93 | 29.08 | 29.01 | 28.54 |
| Support 2 (S2) | 28.44 | 28.74 | 28.48 | 28.48 | |
| Support 3 (S3) | 28.13 | 28.44 | 28.41 | ||
| Support 4 (S4) | 28.22 |
